$OMER
OMEROS CORP

2021 Q1 Form 10-Q Financial Statement

#000155837021006671 Filed on May 10, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q1
Revenue $21.06M $23.54M
YoY Change -10.52% 8.07%
Cost Of Revenue $263.0K $267.0K
YoY Change -1.5% 103.82%
Gross Profit $20.80M $23.27M
YoY Change -10.62% 7.49%
Gross Profit Margin 98.75% 98.87%
Selling, General & Admin $18.05M $18.04M
YoY Change 0.06% 23.31%
% of Gross Profit 86.79% 77.52%
Research & Development $32.50M $28.91M
YoY Change 12.43% 10.12%
% of Gross Profit 156.28% 124.24%
Depreciation & Amortization $390.0K $400.0K
YoY Change -2.5% 5.26%
% of Gross Profit 1.88% 1.72%
Operating Expenses $32.50M $28.91M
YoY Change 12.43% -29.52%
Operating Profit -$45.29M -$23.68M
YoY Change 91.28% 23.07%
Interest Expense $4.897M $5.903M
YoY Change -17.04% 5.41%
% of Operating Profit
Other Income/Expense, Net $418.0K $549.0K
YoY Change -23.86% 11.13%
Pretax Income -$35.09M -$29.03M
YoY Change 20.87% 19.22%
Income Tax
% Of Pretax Income
Net Earnings -$35.09M -$29.03M
YoY Change 20.87% 19.25%
Net Earnings / Revenue -166.61% -123.34%
Basic Earnings Per Share -$0.57
Diluted Earnings Per Share -$0.57 -$534.6K
COMMON SHARES
Basic Shares Outstanding 61.93M 54.21M
Diluted Shares Outstanding 61.93M

Balance Sheet

Concept 2021 Q1 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $100.5M $54.00M
YoY Change 86.11% 14.41%
Cash & Equivalents $9.000M $7.100M
Short-Term Investments $91.50M $46.90M
Other Short-Term Assets $6.000M $6.300M
YoY Change -4.76% 50.0%
Inventory $1.191M $1.211M
Prepaid Expenses
Receivables $24.60M $24.00M
Other Receivables $250.0K $106.0K
Total Short-Term Assets $132.5M $85.61M
YoY Change 54.75% 11.37%
LONG-TERM ASSETS
Property, Plant & Equipment $27.20M $3.355M
YoY Change 710.73% -25.09%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.800M $2.200M
YoY Change -18.18% -8.33%
Total Long-Term Assets $28.96M $32.60M
YoY Change -11.17% 33.76%
TOTAL ASSETS
Total Short-Term Assets $132.5M $85.61M
Total Long-Term Assets $28.96M $32.60M
Total Assets $161.4M $118.2M
YoY Change 36.57% 16.76%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $11.50M $12.96M
YoY Change -11.27% 82.0%
Accrued Expenses $28.13M $41.38M
YoY Change -32.01% 18.83%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $1.200M
YoY Change -53.14%
Total Short-Term Liabilities $43.43M $57.94M
YoY Change -25.03% 30.18%
LONG-TERM LIABILITIES
Long-Term Debt $312.2M $162.0M
YoY Change 92.72% 5.81%
Other Long-Term Liabilities $27.80M $30.10M
YoY Change -7.64% 21.86%
Total Long-Term Liabilities $340.0M $192.1M
YoY Change 76.99% 8.04%
TOTAL LIABILITIES
Total Short-Term Liabilities $43.43M $57.94M
Total Long-Term Liabilities $340.0M $192.1M
Total Liabilities $383.4M $250.1M
YoY Change 53.3% 12.51%
SHAREHOLDERS EQUITY
Retained Earnings -$912.5M -$763.6M
YoY Change 19.49% 13.22%
Common Stock $690.5M $631.8M
YoY Change 9.3% 128834.29%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$222.0M -$131.9M
YoY Change
Total Liabilities & Shareholders Equity $161.4M $118.2M
YoY Change 36.57% 16.76%

Cashflow Statement

Concept 2021 Q1 2020 Q1
OPERATING ACTIVITIES
Net Income -$35.09M -$29.03M
YoY Change 20.87% 19.25%
Depreciation, Depletion And Amortization $390.0K $400.0K
YoY Change -2.5% 5.26%
Cash From Operating Activities -$40.25M -$9.141M
YoY Change 340.37% -29.4%
INVESTING ACTIVITIES
Capital Expenditures $12.00K $66.00K
YoY Change -81.82% -63.74%
Acquisitions
YoY Change
Other Investing Activities $33.00M $10.84M
YoY Change 204.43% -5.49%
Cash From Investing Activities $32.99M $10.78M
YoY Change 206.1% -4.53%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 5.796M 2.399M
YoY Change 141.6% -1743.15%
NET CHANGE
Cash From Operating Activities -40.25M -9.141M
Cash From Investing Activities 32.99M 10.78M
Cash From Financing Activities 5.796M 2.399M
Net Change In Cash -1.473M 4.034M
YoY Change -136.51% -323.24%
FREE CASH FLOW
Cash From Operating Activities -$40.25M -$9.141M
Capital Expenditures $12.00K $66.00K
Free Cash Flow -$40.27M -$9.207M
YoY Change 337.34% -29.88%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2021Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001285819
CY2021Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
61671231
CY2021Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
62252012
CY2021Q1 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:ProductMember
CY2020Q1 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:ProductMember
CY2021Q1 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
us-gaap:ProductMember
CY2020Q1 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
us-gaap:ProductMember
CY2021Q1 dei Security12b Title
Security12bTitle
Common Stock
CY2021Q1 dei Trading Symbol
TradingSymbol
OMER
CY2021Q1 dei Amendment Flag
AmendmentFlag
false
CY2021Q1 dei Document Type
DocumentType
10-Q
CY2021Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2021Q1 dei Document Period End Date
DocumentPeriodEndDate
2021-03-31
CY2021Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2021Q1 dei Entity File Number
EntityFileNumber
001-34475
CY2021Q1 dei Entity Registrant Name
EntityRegistrantName
OMEROS CORPORATION
CY2021Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
WA
CY2021Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
91-1663741
CY2021Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
201 Elliott Avenue West
CY2021Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Seattle
CY2021Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
WA
CY2021Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
98119
CY2021Q1 dei City Area Code
CityAreaCode
206
CY2021Q1 dei Local Phone Number
LocalPhoneNumber
676-5000
CY2021Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2021Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2021Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021Q1 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
62328370
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9028000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10501000
CY2021Q1 us-gaap Short Term Investments
ShortTermInvestments
91455000
CY2020Q4 us-gaap Short Term Investments
ShortTermInvestments
124452000
CY2021Q1 us-gaap Receivables Net Current
ReceivablesNetCurrent
24826000
CY2020Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
3841000
CY2021Q1 us-gaap Inventory Net
InventoryNet
1191000
CY2020Q4 us-gaap Inventory Net
InventoryNet
1355000
CY2021Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5982000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
11136000
CY2021Q1 us-gaap Assets Current
AssetsCurrent
132482000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
151285000
CY2021Q1 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
2173000
CY2020Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
2551000
CY2021Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
24994000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
25526000
CY2021Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1054000
CY2020Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1055000
CY2021Q1 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
741000
CY2020Q4 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
625000
CY2021Q1 us-gaap Assets
Assets
161444000
CY2020Q4 us-gaap Assets
Assets
181042000
CY2021Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
11499000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4199000
CY2021Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
28132000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
28755000
CY2021Q1 omer Operating And Finance Lease Liability Current
OperatingAndFinanceLeaseLiabilityCurrent
3803000
CY2020Q4 omer Operating And Finance Lease Liability Current
OperatingAndFinanceLeaseLiabilityCurrent
3782000
CY2021Q1 us-gaap Liabilities Current
LiabilitiesCurrent
43434000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
36736000
CY2021Q1 omer Operating And Finance Lease Liability Noncurrent
OperatingAndFinanceLeaseLiabilityNoncurrent
27806000
CY2020Q4 omer Operating And Finance Lease Liability Noncurrent
OperatingAndFinanceLeaseLiabilityNoncurrent
28770000
CY2021Q1 us-gaap Senior Long Term Notes
SeniorLongTermNotes
312159000
CY2020Q4 us-gaap Senior Long Term Notes
SeniorLongTermNotes
236288000
CY2021Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2021Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000
CY2021Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2021Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
62252012
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
61671231
CY2021Q1 us-gaap Common Stock Value
CommonStockValue
622000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
616000
CY2021Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
689882000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
751304000
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-912459000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-872672000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-221955000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-120752000
CY2021Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
161444000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
181042000
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
21061000
CY2020Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
23537000
CY2021Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
263000
CY2020Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
267000
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
33358000
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
28911000
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
18052000
CY2020Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
18036000
CY2021Q1 us-gaap Costs And Expenses
CostsAndExpenses
51673000
CY2020Q1 us-gaap Costs And Expenses
CostsAndExpenses
47214000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-30612000
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-23677000
CY2021Q1 us-gaap Interest Expense
InterestExpense
4897000
CY2020Q1 us-gaap Interest Expense
InterestExpense
5903000
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
419000
CY2020Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
402000
CY2020Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
549000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-35090000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-29031000
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-35090000
CY2020Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-29031000
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.57
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.53
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
61928511
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
54299813
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-35090000
CY2020Q1 us-gaap Profit Loss
ProfitLoss
-29031000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
3271000
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
3476000
CY2021Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
396000
CY2020Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
2533000
CY2021Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
390000
CY2021Q1 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
20985000
CY2020Q1 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-11068000
CY2021Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-164000
CY2020Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
64000
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-5038000
CY2020Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-628000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
6562000
CY2020Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1847000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-40254000
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9141000
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
12000
CY2020Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
66000
CY2021Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
3000
CY2020Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
3176000
CY2021Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
33000000
CY2020Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
14018000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
32985000
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
10776000
CY2021Q1 omer Proceeds From Stock Options And Warrants Exercised
ProceedsFromStockOptionsAndWarrantsExercised
6333000
CY2020Q1 omer Proceeds From Stock Options And Warrants Exercised
ProceedsFromStockOptionsAndWarrantsExercised
2712000
CY2021Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
241000
CY2021Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
296000
CY2020Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
313000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5796000
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2399000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1473000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
4034000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10501000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3084000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9028000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7118000
CY2021Q1 us-gaap Interest Paid Net
InterestPaidNet
5995000
CY2020Q1 us-gaap Interest Paid Net
InterestPaidNet
89000
CY2020Q1 us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
22000
CY2021Q1 us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 12.25pt;">Description of Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">We are a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system, addiction and immune-related diseases, including cancers. Our first drug product, OMIDRIA<sup style="background-color:#ffffff;font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup><span style="background-color:#ffffff;"> (phenylephrine and ketorolac intraocular solution) 1%/0.3%</span>, is marketed in the United States (“U.S.”) for use during cataract surgery or intraocular lens replacement. In December 2020, the Centers for Medicare &amp; Medicaid Services (“CMS”) confirmed that OMIDRIA qualifies for separate payment when used on Medicare Part B patients in ambulatory surgery centers (“ASCs”), effective retroactively as of October 1, 2020. OMIDRIA’s pass through status, which had allowed for separate payment when used on Medicare Part B patients in the ASC or hospital setting, had expired on October 1, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Our drug candidate narsoplimab is the subject of a biologics license application (“BLA”) under priority review by the U.S. Food and Drug Administration (“FDA”) for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (“HSCT-TMA”). We also have multiple late-stage clinical development programs in our pipeline, which are focused on: complement-mediated disorders, including immunoglobulin A (“IgA”) nephropathy, atypical hemolytic uremic syndrome (“aHUS”) and COVID-19. </p>
CY2021Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 12.25pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant items subject to such estimates include revenue recognition, stock-based compensation expense and accruals for clinical trials as well as manufacturing of drug product. We base our estimates on historical experience and on various other factors, including the impact of the COVID-19 pandemic, that we believe are reasonable under the circumstances; however, actual results could differ from these estimates.</p>
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3453133
CY2020Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1669930
CY2021Q1 us-gaap Accounts Receivable Net
AccountsReceivableNet
24576000
CY2020Q4 us-gaap Accounts Receivable Net
AccountsReceivableNet
3771000
CY2021Q1 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
250000
CY2020Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
70000
CY2021Q1 us-gaap Receivables Net Current
ReceivablesNetCurrent
24826000
CY2020Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
3841000
CY2021Q1 us-gaap Contract With Customer Refund Liability Current
ContractWithCustomerRefundLiabilityCurrent
1500000
CY2020Q4 us-gaap Contract With Customer Refund Liability Current
ContractWithCustomerRefundLiabilityCurrent
1200000
CY2021Q1 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
242000
CY2020Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
109000
CY2021Q1 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
405000
CY2020Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
462000
CY2021Q1 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
544000
CY2020Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
784000
CY2021Q1 us-gaap Inventory Net
InventoryNet
1191000
CY2020Q4 us-gaap Inventory Net
InventoryNet
1355000
CY2021Q1 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
10210000
CY2021Q1 omer Accrued Contract Research Costs
AccruedContractResearchCosts
6146000
CY2020Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
10198000
CY2021Q1 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
8037000
CY2020Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
7647000
CY2021Q1 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
2173000
CY2020Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
2551000
CY2020Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
400000
CY2021Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
400000
CY2021Q1 omer Accrued Sales Rebates Fees And Discounts Current
AccruedSalesRebatesFeesAndDiscountsCurrent
6871000
CY2020Q4 omer Accrued Sales Rebates Fees And Discounts Current
AccruedSalesRebatesFeesAndDiscountsCurrent
3326000
CY2020Q4 omer Accrued Contract Research Costs
AccruedContractResearchCosts
7952000
CY2021Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
5002000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
5393000
CY2021Q1 us-gaap Interest Payable Current
InterestPayableCurrent
3703000
CY2020Q4 us-gaap Interest Payable Current
InterestPayableCurrent
5205000
CY2021Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3665000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3948000
CY2021Q1 omer Accrued Clinical Trial Costs
AccruedClinicalTrialCosts
2007000
CY2020Q4 omer Accrued Clinical Trial Costs
AccruedClinicalTrialCosts
2121000
CY2021Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
738000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
810000
CY2021Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
28132000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
28755000
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9000000.0
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10500000
CY2021Q1 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
0
CY2020 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
0
CY2021Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
320030000
CY2021Q1 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
7871000
CY2021Q1 us-gaap Long Term Debt
LongTermDebt
312159000
CY2020Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
320030000
CY2020Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
77645000
CY2020Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
6097000
CY2020Q4 us-gaap Long Term Debt
LongTermDebt
236288000
CY2021Q1 omer Number Of Options To Extend Lease Term
NumberOfOptionsToExtendLeaseTerm
2
CY2021Q1 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P5Y
CY2021Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
1583000
CY2020Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
1509000
CY2021Q1 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
323000
CY2020Q1 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
357000
CY2021Q1 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
63000
CY2020Q1 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
89000
CY2021Q1 us-gaap Variable Lease Cost
VariableLeaseCost
813000
CY2020Q1 us-gaap Variable Lease Cost
VariableLeaseCost
542000
CY2021Q1 us-gaap Sublease Income
SubleaseIncome
418000
CY2020Q1 us-gaap Sublease Income
SubleaseIncome
293000
CY2021Q1 us-gaap Lease Cost
LeaseCost
2364000
CY2020Q1 us-gaap Lease Cost
LeaseCost
2204000
CY2021Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
3381000
CY2020Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
2136000
CY2021Q1 us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
354000
CY2020Q1 us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
402000
CY2021Q1 omer Cashless Exercise Of Warrants
CashlessExerciseOfWarrants
43115
CY2021Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
200000
CY2021Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
23.00
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-120752000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
6333000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
241000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
3271000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-35090000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-221955000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-109021000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2712000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
3476000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-29031000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-131864000
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3271000
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3476000
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
15.26
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
11938528
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
11.92
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
244500
CY2021Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
19.09
CY2021Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
555880
CY2021Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
11.39
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
69603
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
11557545
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
12.08
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y10M24D
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
67933000
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
11223195
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
12.03
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P5Y9M18D
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
66493000
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
8591292
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
11.55
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y10M24D
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
54999000

Files In Submission

Name View Source Status
0001558370-21-006671-index-headers.html Edgar Link pending
0001558370-21-006671-index.html Edgar Link pending
0001558370-21-006671.txt Edgar Link pending
0001558370-21-006671-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
omer-20210331.xsd Edgar Link pending
omer-20210331x10q.htm Edgar Link pending
omer-20210331x10q006.jpg Edgar Link pending
omer-20210331x10q_htm.xml Edgar Link completed
omer-20210331xex31d1.htm Edgar Link pending
omer-20210331xex31d2.htm Edgar Link pending
omer-20210331xex32d1.htm Edgar Link pending
omer-20210331xex32d2.htm Edgar Link pending
omer-20210331_cal.xml Edgar Link unprocessable
omer-20210331_def.xml Edgar Link unprocessable
omer-20210331_lab.xml Edgar Link unprocessable
omer-20210331_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending